or gingival bleeding), as is seen in this case, is typical of disorders of primary hemostasis, including thrombocytopenia, qualitative platelet disorders, and von Willebrand's disease. In contrast, unprovoked hemarthroses and deep soft-tissue hematomas are characteristic of disorders of coagulation, such as hemophilia. In addition, the time of onset of bleeding after vascular trauma differs between platelet and coagulation disorders. Patients with platelet abnormalities tend to bleed immediately after trauma, whereas patients with disorders of coagulation frequently have delayed hemorrhage. Finally, the bleeding in this patient is out of proportion to the effect one might expect from cyclooxygenase inhibition by aspirin.
On physical examination, the patient was a mildly overweight black woman who did not appear to be in acute distress. Her blood pressure was 128/76 mm Hg, pulse 80 beats per minute and regular, respiratory rate 16 breaths per minute, and oxygen saturation 98% while she was breathing ambient air. Examination of the oral cavity revealed blood slowly oozing from the vicinity of the lower-right second molar, with no visible mucosal laceration. There were no oral petechiae, bullae, or ulcers. Mild conjunctival pallor was noted, but no scleral icterus. There was no lymphadenopathy. The lung fields were clear on auscultation and percussion. Cardiac examination revealed mild lateral apical displacement; regular heart rate and rhythm; and no murmur, rub, or gallop. The abdomen was soft and not tender, with normal bowel sounds and no hepatosplenomegaly or masses detected. Rectal examination revealed no masses and a scant amount of brown stool that was negative for occult blood. Her extremities were warm, with brisk capillary refill, and showed no clubbing, cyanosis, or edema. No rashes, petechiae, ecchymoses, or telangiectasias were noted. Neurologic examination revealed normal cranial nerves, muscle strength, sensation, deep-tendon reflexes, coordination, and gait.
The patient presented with prolonged bleeding at the site of oral surgery, but the physical examination showed no evidence of spontaneous bleeding, such as petechiae, ecchymoses, or hemarthroses. These findings point toward a disorder of primary hemostasis. The initial evaluation should include three measurements: the platelet count, prothrombin time, and activated partial-thromboplastin time. With the results of these tests, the differential diagnosis can be narrowed (Table 1) and then further delineated by means of more specific tests. Some experts also recommend testing to assess platelet function, such as measurement of bleeding time or measurement of platelet adhesion and aggregation. However, owing to technical factors in execution, these tests are subject to substantial variation and are not universally viewed as helpful.
The white-cell count was 6200 per cubic millimeter, with 49% polymorphonuclear cells, 37% lymphocytes, and 13% monocytes. The hematocrit was 31.8%, with a mean corpuscular volume of 93 fl. The platelet count was 352,000 per cubic millimeter. The blood urea nitrogen level was 18 mg per deciliter (6.4 mmol per liter), the creatinine level 1.4 mg per deciliter (124 μmol per liter), the glucose level 88 mg per deciliter (4.8 mmol per liter), the calcium level 10.2 mg per deciliter (2.6 mmol per liter), the total protein level 8.6 g per deciliter, and the albumin level 3.9 g per deciliter. Electrolytes were in the normal range, as were the findings on liver-function tests. The thyroid-stimulating hormone level was 1.7 μU per milliliter. Results of urinalysis were normal, with no hematuria, proteinuria, or casts. The prothrombin time was 13.7 seconds (normal range, 11.8 to 14.6), and the activated partial-thromboplastin time was 49.6 seconds (normal range, 23.8 to 36.6).
This patient has a prolonged activated partialthromboplastin time with a normal prothrombin time and a normal platelet count. A prolonged activated partial-thromboplastin time with a normal prothrombin time may be due to a deficiency or inhibition of any of the factors that are unique to the intrinsic pathway of the coagulation cascade -namely, factors VIII, IX, and XI (Table 1) . Since von Willebrand factor serves as a stabilizing carrier of factor VIII within the circulation, deficiencies in von Willebrand factor, as occur in von Willebrand's disease, can also prolong the activated partial-thromboplastin time. In addition, certain medications (e.g., unfractionated heparin and some other direct thrombin inhibitors) cause an isolated prolongation of the activated partial-thromboplastin time. However, this patient is not receiving such medications. Finally, deficiencies of factor XII, prekallikrein, and high-molecular-weight kininogen, as well as the presence of a lupus anti- 1889 coagulant, may prolong the activated partialthromboplastin time, but these conditions are not typically associated with a bleeding diathesis. Given the acquired nature of the bleeding disorder in this patient, a coagulation-factor inhibitor is much more likely to be responsible than is a factor deficiency. Acquired factor inhibitors have been associated with several conditions and settings, including pregnancy, thoracic surgery, use of certain medications, viral infections, lymphomas and other cancers, and autoimmune disorders. To distinguish between the presence of an inhibitor and a deficiency state, coagulation studies should be performed with a 1:1 mixture of the patient's plasma and normal plasma. Normalization of the activated partial-thromboplastin time is consistent with a factor deficiency, whereas persistent prolongation of the activated partial-thromboplastin time indicates the presence of a factor inhibitor. Screening tests for von Willebrand's disease, including assays of von Willebrand factor antigen, ristocetin cofactor activity, and factor VIII activity, should also be performed.
Also of note is the patient's mild normocytic anemia, elevated total protein concentration with a calculated serum globulin concentration of 4.7 g per deciliter, and mild renal insufficiency. Although we are not told whether these findings are new, they raise concern about a possible underlying systemic illness. Further testing should include a fecal occult-blood test, iron studies, a review of the peripheral-blood smear, and serum protein electrophoresis.
The serum iron level was 27 μg per deciliter (4.8 μmol per liter), the ferritin level 76 ng per milliliter, and the total iron-binding capacity 314 μg per deciliter (56.2 μmol per liter). Levels of vitamin B 12 and folate were normal. The reticulocyte count was 2.7%, and the peripheral-blood smear showed mild erythrocyte anisocytosis but was otherwise normal. Factor VIII activity was 20% (normal range, 50 to 150), the von Willebrand factor antigen level was 22% (normal range, 50 to 160), and ristocetin cofactor activity was 14% (normal range, 50 to 160). Gel electrophoresis of von Willebrand factor multimers showed loss of the high-molecular-weight forms (Fig. 1) . The activated partial-thromboplastin time was corrected on a plasma mixing test.
The reduced factor VIII activity is consistent with -but not diagnostic of -von Willebrand's disease, since it is also seen in a state of factor VIII inhibition or deficiency. However, the low levels of plasma von Willebrand factor antigen and reduced ristocetin cofactor activity do confirm the diagnosis of von Willebrand's disease. Ristocetin is an antibiotic that binds to von Willebrand factor, inducing a conformational change that facilitates glycoprotein Ib-mediated platelet binding of von Willebrand factor. Whereas measurement of von Willebrand factor antigen provides a quantitative assessment of von Willebrand factor levels, the ristocetin cofactor assay evaluates the functional capacity of von Willebrand factor to participate in platelet-plug formation.
When either the von Willebrand factor antigen level or the ristocetin cofactor activity is reduced, von Willebrand factor multimer gel electrophoresis should be performed. Selective loss of highmolecular-weight von Willebrand factor multimers with relatively normal concentrations of smaller multimers is typical of acquired von Willebrand's disease; also typical is a level of von Willebrand factor antigen that exceeds the level of ristocetin cofactor activity. Although a similar pattern is also seen in some types of congenital von Willebrand's disease (type II variants), the absence of prior abnormal bleeding in this case is evidence of an acquired disorder. Thus, the patient has acquired von Willebrand's disease with low levels of circulating von Willebrand factor and consequently low levels of factor VIII that prolong the activated partialthromboplastin time.
The observation that the prolonged activated partial-thromboplastin time returned to normal after the patient's plasma was mixed with normal plasma in a ratio of 1:1 (vol/vol) suggests a factor deficiency. In contrast to an acquired factor VIII inhibitor (which would result in an activated partial-thromboplastin time that remained prolonged on a mixing test), acquired anti-von Willebrand factor antibodies typically do not inhibit factor VIII functional activity and are believed to cause deficiencies of von Willebrand factor and factor VIII by enhancing their clearance.
Several disorders have been linked to acquired von Willebrand's disease, including lymphoproliferative and myeloproliferative disorders. Given the anemia, elevated serum globulin concentration, and mildly elevated creatinine concentration in this patient, one must consider the possibility of multiple myeloma as the cause of her acquired von Willebrand's disease. Serum protein electrophoreses should be carried out. A bone marrow aspirate (Fig. 2) .
The patient has an IgG kappa monoclonal gammopathy with low levels of IgA and low-to-normal levels of IgM. The findings of more than 10% plasma cells on bone marrow biopsy and accompanying anemia are diagnostic of multiple myeloma; this condition is known to be associated with acquired von Willebrand's disease.
Management of acquired von Willebrand's disease includes treatment of bleeding and the prevention of perioperative hemorrhage, but it also requires treatment of the myeloma or other underlying disorder. Agents for the initial treatment and prevention of bleeding include desmopressin and plasma concentrates that contain von Willebrand factor. Desmopressin is typically favored over von Willebrand factor-containing plasma concentrates because it is readily available, costs less, and precludes transfusion-associated risks. However, the increase in the von Willebrand factor concentration with the use of desmopressin is generally less than that obtained with the concentrates, and transfusion of donor von Willebrand factor remains an important option in patients with severe von Willebrand factor deficiency or severe hemorrhage.
The benefits of desmopressin and von Wille- 
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Acquired bleeding disorders are often manifested in a striking manner and leave a lasting impression on patients and providers alike. The clinical pattern of bleeding provides important clues regarding its origin. Mucocutaneous bleeding is typically caused by quantitative or qualitative platelet disorders or von Willebrand's disease, whereas spontaneous soft-tissue bleeding and hemarthroses are most commonly related to disorders of coagulation. In this patient with gingival bleeding, a prolonged activated partial-thromboplastin time, and a normal prothrombin time and platelet count, the clinician was rapidly able to establish a diagnosis of acquired von Willebrand's disease. After it is synthesized by endothelial cells and megakaryocytes, von Willebrand factor is assembled into multimers. several agonists, including epinephrine, thrombin, fibrin, histamine, and desmopressin. 2 The largest of these multimers (known as ultralarge von Willebrand factor multimers) are cleaved by the metalloproteinase ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) into the somewhat smaller forms normally seen in the circulation. 3 Von Willebrand factor plays a key role in both platelet-plug and fibrin-clot formation. When endothelial damage occurs, von Willebrand factor multimers bind to the exposed subendothelial connective-tissue macromolecules (collagen, fibronectin, and glycosaminoglycans) and to platelets, forming an adhesive bridge between the two and paving the way for platelet adhesion and aggregation at the site of injury. The von Willebrand factor also serves as a carrier for factor VIII, protecting it from proteolysis by activated protein C and protein S and increasing its half-life by a factor of five. 2 The prevalence of congenital von Willebrand's disease ranges from 30 to 100 cases per 1 million persons, 1 and acquired von Willebrand's disease is even less common. 4 Acquired von Willebrand's disease has been reported in association with a number of different conditions, and its pathobiologic mechanisms are just as diverse (Fig. 3) . Circulating antibodies to von Willebrand factor have been reported in patients with lymphoproliferative disorders, 5 plasma-cell dyscrasias, 6,7 and autoimmune conditions 8 such as systemic lupus erythe- Multiple molecular mechanisms can lead to acquired von Willebrand's disease: shearing of high-molecular-weight von Willebrand factor multimers by mechanical stress or proteolysis catalyzed by ADAMTS 13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) in cardiac valvulopathies, degradation of von Willebrand factor multimers by plasmin in disseminated intravascular coagulation, and reduction of von Willebrand factor synthesis in hypothyroidism. In lymphoproliferative disorders, plasma-cell dyscrasias, and autoimmune diseases, circulating anti-von Willebrand factor antibodies can cause qualitative or quantitative deficiencies, and tumor cells can adsorb von Willebrand factor (e.g., by expressing glycoprotein Ib), depleting its circulating levels.
The clinical problem-solving receptor on platelets, has been reported in a patient with monoclonal gammopathy of undetermined significance 10 and in some cases may underlie the selective binding of von Willebrand factor to tumor cells (Fig. 3) . Because of the variety of mechanisms responsible for acquired von Willebrand's disease, different therapeutic options are often explored to determine which will provide the best response in an individual patient. 1 In addition to treatment with desmopressin and von Willebrand factorcontaining concentrates, high doses of immune globulin given intravenously can be used to delay clearance of both native and infused von Willebrand factor, and recombinant factor VIIa can be used for patients with refractory bleeding or those about to undergo major surgery. Other medications, including corticosteroids and immunosuppressive or chemotherapeutic agents, have been used when patients with acquired von Willebrand's disease have ongoing or repeated episodes of bleeding.
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